Reuters logo
10 months ago
BRIEF-Genocea's Genital Herpes Immunotherapy GEN-003 demonstrates significant reduction of viral shedding in phase 2b clinical trial
September 29, 2016 / 12:02 PM / 10 months ago

BRIEF-Genocea's Genital Herpes Immunotherapy GEN-003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

1 Min Read

Sept 29 (Reuters) - Genocea Biosciences, Inc. :

* Study achieved its primary endpoint

* Genocea's Genital Herpes Immunotherapy GEN003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

* Phase 3 expected to start in 2h 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below